GSK plc vs Western Alliance Bancorporation — how do they compare? GSK plc trades at $50.5 (market cap $102.60B), while Western Alliance Bancorporation trades at $81.46 (market cap $8.89B). The key difference: GSK plc is far larger — about 11.5× Western Alliance Bancorporation's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | WAL | |
|---|---|---|
Market Cap | $102.60B | $8.89B |
Sector | Health | Financials |
52-Week High | $61.18 | $96.08 |
52-Week Low | $38.22 | $66.70 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | 2.06% |
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →